Resources Archive - Page 26 of 48

Upregulation of drug metabolism enzymes mediates ADC resistance in a HER2-positive cancer cell line

SITC Poster #1162: Enhertu is currently approved for the treatment of patients with HER2-positive breast cancer, gastric cancer, or HER2-mutant...

Covalent Fragment-based Drug Discovery: BTK Inhibitors

At the Covalent Drug Discovery 2023 Summit and Fragments 2024 Conference, we presented a case study on Bruton’s tyrosine kinase (BTK)...

Novel Approaches to Targeted Protein Degradation

In the last decade, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific...

One Stop Target-to-Hit Platform: Helicases

RecQ helicases (BLM, WRN, RECQL, RECQL4, and RECQL5) are an important family of surveillance proteins that play critical roles in...

Pioneering Advanced Modalities in Early Drug Discovery

New modalities such as peptides, oligonucleotides, and cell and gene therapies have revolutionized healthcare industry innovation. To meet these evolving...

One Stop Target-to-Hit Platform: CDKs and CDK-Cyclin Complexes

Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer...

Colitis-Associated Cancer Mouse Model

The cumulative impact of chronic inflammation in patients with inflammatory bowel disease (IBD) predisposes them to the development of IBD-associated...

In Vivo Models of Tumor Complications

Tumors and anti-tumor therapies may cause diverse systemic complications. Treatment of these complications is essential in optimizing quality of life...

Fibrosis Models in Mice and Rats

Selecting preclinical in vivo models that are reflective of clinical outcome is a key challenge in the development of new...

Knowledge Library